Larson Financial Group’s Blueprint Medicines BPMC Stock Holding History

Larson Financial Group’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3	Closed	-$385	–	3460
2025 Q2	$385	Buy	3 +1	+50%	+$104	﹤0.01%	2923
2025 Q1	$177	Buy	+2	New	+$195	﹤0.01%	2816

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Larson Financial Group's BPMC Position: Q3 2025 in Review

Larson Financial Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 3 shares — an estimated $385 sold.

Larson Financial Group first reported a position in BPMC in Q1 2025 and held it in 2 quarters. The position peaked at $385 in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Larson Financial Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Larson Financial Group sold 3 Blueprint Medicines shares in Q3 2025, an estimated $385.
Larson Financial Group first reported a position in Blueprint Medicines in Q1 2025 and held it in 2 quarters.
Larson Financial Group's Blueprint Medicines position peaked at $385 in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Larson Financial Group's 13F filing for Q3 2025, filed 14 Nov 2025.